Hypogonadism
Drug research and approvals for hypogonadism: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 22, 2026, 44 studies of hypogonadism are recruiting on ClinicalTrials.gov, Health Canada has authorized 0 drug trials for it since 2013, and FDA has 2 approved and 2 open orphan designations naming it.
- Recruiting worldwide: 44
- Trials authorized in Canada: 0
- FDA orphan approvals: 2
- EU medicines: 0
- Exercise Self-Efficacy, Body Composition, and Physical Activity in Men With HypogonadismNCT07924514 · Not reported · Hacettepe University · starts Oct 20, 2026
- Safety and Efficacy of Weekly Testosterone Cypionate Auto-Injector in Men With HypogonadismNCT07898072 · Phase 3 · Amneal Pharmaceuticals, LLC · starts Sep 28, 2026
- Anticipated Stigma, Illness Identity, and Quality of Life in Male HypogonadismNCT07752511 · Not reported · Hacettepe University · starts Oct 20, 2026
- A Multiple Baseline Feasibility Trial of Social Management Training for People With Sex Chromosome AneuploidiesNCT07718997 · Phase 1 · University of Oslo · starts Jun 1, 2026
- Feasibility of a Digital Self-help Program for Functional Hypothalamic Amenorrhea (HEAL-FHA Pilot)NCT07589868 · Not applicable · Karolinska Institutet · starts Nov 2, 2026
- Male Experiences With Intra Cytoplasmic Sperm Injection (ICSI) and Reduced Sperm QualityNCT07546435 · Not reported · Peter Humaidan · starts Feb 13, 2026
- Clinical Trial to Observe the Effects of Tamoxifen on Testosterone Recovery in Medically Castrated Prostate Cancer…NCT07535905 · Phase 2 · University Health Network, Toronto · starts Dec 31, 2026
- Anthropometric, Functional and Lifestyle Factors Associated With Testosterone Levels in Middle-Aged MenNCT07476222 · Not reported · Andijan State Medical Institute · starts Jun 1, 2026
- Perception of Hormonal Replacement Therapy Among Patients Aged 11 to 17 YearsNCT07315932 · Not reported · University Hospital, Strasbourg, France · starts Mar 23, 2025
Approved 16
- TestosteroneAndrogen Receptor agonist
- Testosterone undecanoateAndrogen Receptor agonist
- Testosterone enanthateAndrogen Receptor agonist
- Testosterone cypionateAndrogen Receptor agonist
- Estradiol valerateEstrogen receptor alpha agonist
- Estrone sulfuric acidEstrogen receptor alpha agonist
- Estrogens, conjugatedEstrogen receptor agonist
- Estrogens, esterifiedEstrogen receptor agonist
- Norethindrone acetateProgesterone receptor agonist
- Choriogonadotropin alfaLuteinizing hormone/Choriogonadotropin receptor agonist
- FollitropinFollicle stimulating hormone receptor agonist
- Follitropin betaFollicle stimulating hormone receptor agonist
- MethyltestosteroneAndrogen Receptor agonist
- FluoxymesteroneAndrogen Receptor agonist
- BromocriptineD2-like dopamine receptor agonist
- Follitropin alfaFollicle stimulating hormone receptor agonist
Phase 3 9
- EnclomipheneEstrogen receptor alpha modulator
- DutasterideSteroid 5-alpha-reductase inhibitor
- Gonadotropin, chorionicLuteinizing hormone/Choriogonadotropin receptor agonist
- GonadorelinGonadotropin-releasing hormone receptor agonist
- Corifollitropin alfaFollicle stimulating hormone receptor agonist
- Insulin humanInsulin receptor agonist
- CholecalciferolVitamin D receptor agonist
- LetrozoleCytochrome P450 19A1 inhibitor
- MenotropinsLuteinizing hormone/Choriogonadotropin receptor agonist
Phase 2 12
- FispemifeneEstrogen receptor modulator
- AcylineGonadotropin-releasing hormone receptor antagonist
- KetoconazoleCytochrome P450 51 inhibitor
- AnastrozoleCytochrome P450 19A1 inhibitor
- NaloxoneOpioid receptors; mu/kappa/delta antagonist
- Kisspeptin-10
- Lutropin alfaLuteinizing hormone/Choriogonadotropin receptor agonist
- LeuprolideGonadotropin-releasing hormone receptor agonist
- ClomipheneEstrogen receptor alpha modulator
- TAK-448
- Stanolone
- Kisspeptin
Phase 1 or earlier 3
- FinasterideSteroid 5-alpha-reductase 2 inhibitor
- RelugolixGonadotropin-releasing hormone receptor antagonist
- Curcumin
How its trials ended
345 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 87 whose ending is known, 46% met their primary endpoint, 7% missed it and 47% stopped early.
- Completed, result not reported18453%
- Ongoing5215%
- Met its primary endpoint4012%
- Stopped: other or unclear257%
- Status unknown226%
- Stopped: enrollment or feasibility82%
- Missed its primary endpoint62%
- Stopped: lack of efficacy21%
- Stopped: safety21%
- Stopped: sponsor or business decision21%
- Stopped: funding21%
| Oct 8, 2004 | LuverisLuveris (lutropin alfa for injection), concomitantly administered with Gonal-f (follitropin alfa for injection), is indicated for… | EMD Serono, Inc. | Approved |
| May 24, 2000 | Gonal-FFor the induction of spermatogenesis in men with primary and secondary hypogonadotropic hypogonadism in whom the cause of infertility is… | EMD Serono, Inc. | Approved |
| Dec 5, 1997 | UrofollitropinFor the initiation and re-initiation of spermatogenesis in adult males with reproductive failure due to hypothalamic or pituitary… | EMD Serono, Inc. | Designated |
| Sep 1, 1987 | SomatropinAdjunct for the induction of ovulation in women with infertility due to hypogonadotropic hypogonadism or bilateral tubal occlusion or… | Novo Nordisk Pharmaceuticals | Designated |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA